Century Therapeutics (IPSC) Share-based Compensation (2020 - 2026)

Century Therapeutics (IPSC) has reported Share-based Compensation for 7 consecutive years, with $6.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Share-based Compensation rose 169.58% year-over-year to $6.5 million; the TTM figure through Mar 2026 stood at $6.5 million (down 45.07% YoY), while the FY2025 annual figure was $6.8 million, down 46.09% from the prior year.
• Share-based Compensation advanced to $6.5 million in Q1 2026 per IPSC's latest filing, from $1.3 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $6.5 million in Q1 2026 and bottomed at $1.3 million in Q4 2025.
• Historically, Share-based Compensation has averaged $3.1 million across 5 years, with a median of $3.0 million in 2022.
• Annual changes were most pronounced in 2022 — Share-based Compensation surged 2405.26% — and 2025, when it sank 51.13%.
• Century Therapeutics' Share-based Compensation stood at $2.7 million in 2022, then soared by 30.38% to $3.6 million in 2023, then fell by 25.32% to $2.7 million in 2024, then tumbled by 51.13% to $1.3 million in 2025, then jumped by 403.08% to $6.5 million in 2026.
• Business Quant data shows IPSC's Share-based Compensation at $6.5 million in Q1 2026, $1.3 million in Q4 2025, and $2.2 million in Q2 2025.